Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $3.98 billion. The enterprise value is $2.83 billion.
| Market Cap | 3.98B |
| Enterprise Value | 2.83B |
Important Dates
The last earnings date was Monday, November 9, 2026, after market close.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 98.28 million shares outstanding. The number of shares has increased by 16.36% in one year.
| Current Share Class | 98.28M |
| Shares Outstanding | 98.28M |
| Shares Change (YoY) | +16.36% |
| Shares Change (QoQ) | +0.16% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 103.04% |
| Float | 92.34M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 353.05 |
| PB Ratio | 3.47 |
| P/TBV Ratio | 3.47 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.19, with a Debt / Equity ratio of 0.01.
| Current Ratio | 21.19 |
| Quick Ratio | 21.01 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -50.27% and return on invested capital (ROIC) is -33.81%.
| Return on Equity (ROE) | -50.27% |
| Return on Assets (ROA) | -32.18% |
| Return on Invested Capital (ROIC) | -33.81% |
| Return on Capital Employed (ROCE) | -40.30% |
| Weighted Average Cost of Capital (WACC) | 4.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.16M |
| Employee Count | 370 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -775,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.02% in the last 52 weeks. The beta is 0.08, so XENE's price volatility has been lower than the market average.
| Beta (5Y) | 0.08 |
| 52-Week Price Change | +2.02% |
| 50-Day Moving Average | 41.13 |
| 200-Day Moving Average | 52.28 |
| Relative Strength Index (RSI) | 54.92 |
| Average Volume (20 Days) | 1,293,984 |
Short Selling Information
The latest short interest is 7.36 million, so 7.49% of the outstanding shares have been sold short.
| Short Interest | 7.36M |
| Short Previous Month | 7.35M |
| Short % of Shares Out | 7.49% |
| Short % of Float | 7.97% |
| Short Ratio (days to cover) | 4.66 |
Income Statement
| Revenue | n/a |
| Gross Profit | -371.08M |
| Operating Income | -465.32M |
| Pretax Income | -429.51M |
| Net Income | -428.73M |
| EBITDA | -463.00M |
| EBIT | -465.32M |
| Earnings Per Share (EPS) | -$4.67 |
Balance Sheet
The company has $1.15 billion in cash and investments and $6.01 million in debt, with a net cash position of $1.15 billion or $11.67 per share.
| Cash & Investments | 1.15B |
| Total Debt | 6.01M |
| Net Cash | 1.15B |
| Net Cash Per Share | $11.67 |
| Equity (Book Value) | 1.15B |
| Book Value Per Share | 11.67 |
| Working Capital | 914.76M |
Cash Flow
In the last 12 months, operating cash flow was -$356.10 million and capital expenditures -$1.01 million, giving a free cash flow of -$357.11 million.
| Operating Cash Flow | -356.10M |
| Capital Expenditures | -1.01M |
| Depreciation & Amortization | 2.32M |
| Net Borrowing | n/a |
| Free Cash Flow | -357.11M |
| FCF Per Share | -$3.63 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
XENE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -16.36% |
| Shareholder Yield | n/a |
| Earnings Yield | -11.55% |
| FCF Yield | -8.98% |
Analyst Forecast
The average price target for XENE is $71.69, which is 77.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $71.69 |
| Price Target Difference | 77.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 217.73% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
XENE has an Altman Z-Score of 48.83 and a Piotroski F-Score of 2.
| Altman Z-Score | 48.83 |
| Piotroski F-Score | 2 |